Small Peptide-based GLP-1R Ligands: an Approach to Reduce the Kidney Uptake of Radiolabeled GLP-1R-targeting Agents?

Overview

Journal EJNMMI Radiopharm Chem

Date 2021 Aug 25

PMID 34432147

Citations 1

Authors

Veronika Barbara Felber

Hans-Jurgen Wester

Affiliations

Soon will be listed here.

Abstract

Aim: Elevated kidney uptake in insulinoma patients remains a major limitation of radiometallated exendin-derived ligands of the glucagon-like peptide 1 receptor (GLP-1R). Based on the previously published potent GLP-1R-activating undecapeptide 1, short-chained GLP-1R ligands were developed to investigate whether kidney uptake can be reduced by means of direct F-labeling (nuclide-based accelerated renal excretion) or the reduction of the overall ligand charge (ligand-based reduced kidney uptake).

Materials & Methods: GLP-1R ligands were prepared according to optimized standard protocols via solid-phase peptide synthesis (SPPS) or, when not practicable, via fragment coupling in solution. Synthesis of (2'-Et, 4'-OMe)4, 4'-L-biphenylalanine ((2'-Et, 4'-OMe)BIP), required for the preparation of 1, was accomplished by Suzuki-Miyaura cross-coupling. In vitro experiments were performed using stably transfected GLP-1R HEK293-hGLP-1R cells.

Results: In contrast to the three reference ligands glucagon-like peptide 1 (GLP-1, IC = 23.2 ± 12.2 nM), [Nle, Tyr(3-I)]exendin-4 (IC = 7.63 ± 2.78 nM) and [Nle, Tyr]exendin-4 (IC = 9.87 ± 1.82 nM), the investigated GLP-1R-targeting small peptides (9-15 amino acids), including lead peptide 1, exhibited only medium to low affinities (IC > 189 nM). Only SiFA-tagged undecapeptide 5 (IC = 189 ± 35 nM) revealed a higher affinity than 1 (IC = 669 ± 242 nM).

Conclusion: The investigated small peptides, including lead peptide 1, could not compete with favorable in vitro characteristics of glucagon-like peptide 1 (GLP-1), [Nle, Tyr(3-I)]exendin-4 and [Nle, Tyr]exendin-4. The auspicious EC values of 1 provided by the literature could not be transferred to competitive binding experiments. Therefore, the use of 1 as a basic scaffold for the design of further GLP-1R-targeting radioligands cannot be recommended. Further investigations might include the scaffold of 5, although substantial optimizations concerning affinity and lipophilicity would be required. In sum, GLP-1R-targeting radioligands with reduced kidney uptake could not be obtained in this work, which emphasizes the need for further ligands addressing this particular issue.

Citing Articles

Reducing the Kidney Uptake of High Contrast CXCR4 PET Imaging Agents via Linker Modifications.

Kwon D, Zhang Z, Zeisler J, Kuo H, Lin K, Benard F Pharmaceutics. 2022; 14(7).

PMID: 35890397 PMC: 9316317. DOI: 10.3390/pharmaceutics14071502.

References

Gotthardt M, Lalyko G, van Eerd-Vismale J, Keil B, Schurrat T, Hower M . A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept. 2006; 137(3):162-7. DOI: 10.1016/j.regpep.2006.07.005. View

Gao H, Niu G, Yang M, Quan Q, Ma Y, Murage E . PET of insulinoma using ¹⁸F-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm. 2011; 8(5):1775-82. PMC: 3185201. DOI: 10.1021/mp200141x. View

Adelhorst K, Hedegaard B, Knudsen L, Kirk O . Structure-activity studies of glucagon-like peptide-1. J Biol Chem. 1994; 269(9):6275-8. View

Mapelli C, Natarajan S, Meyer J, Bastos M, Bernatowicz M, Lee V . Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. J Med Chem. 2009; 52(23):7788-99. DOI: 10.1021/jm900752a. View

Hoang H, Song K, Hill T, Derksen D, Edmonds D, Kok W . Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists. J Med Chem. 2015; 58(9):4080-5. DOI: 10.1021/acs.jmedchem.5b00166. View

Luo Y, Yu M, Pan Q, Wu W, Zhang T, Kiesewetter D . 68Ga-NOTA-exendin-4 PET/CT in detection of occult insulinoma and evaluation of physiological uptake. Eur J Nucl Med Mol Imaging. 2014; 42(3):531-2. PMC: 5223098. DOI: 10.1007/s00259-014-2946-9. View

Brom M, Oyen W, Joosten L, Gotthardt M, Boerman O . 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging. 2010; 37(7):1345-55. PMC: 2886138. DOI: 10.1007/s00259-009-1363-y. View

Lappchen T, Tonnesmann R, Eersels J, Meyer P, Maecke H, Rylova S . Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake. PLoS One. 2017; 12(1):e0170435. PMC: 5245897. DOI: 10.1371/journal.pone.0170435. View

Haque T, Lee V, Riexinger D, Lei M, Malmstrom S, Xin L . Identification of potent 11mer glucagon-like peptide-1 receptor agonist peptides with novel C-terminal amino acids: Homohomophenylalanine analogs. Peptides. 2010; 31(5):950-5. DOI: 10.1016/j.peptides.2010.01.008. View

10.

Gromada J, Rorsman P, Dissing S, Wulff B . Stimulation of cloned human glucagon-like peptide 1 receptor expressed in HEK 293 cells induces cAMP-dependent activation of calcium-induced calcium release. FEBS Lett. 1995; 373(2):182-6. DOI: 10.1016/0014-5793(95)01070-u. View

11.

Vegt E, Melis M, Eek A, de Visser M, Brom M, Oyen W . Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging. 2010; 38(4):623-32. PMC: 3053449. DOI: 10.1007/s00259-010-1685-9. View

12.

Jacobson O, Kiesewetter D, Chen X . Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjug Chem. 2014; 26(1):1-18. PMC: 4306521. DOI: 10.1021/bc500475e. View

13.

Zhang M, Jacobson O, Kiesewetter D, Ma Y, Wang Z, Lang L . Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation. Bioconjug Chem. 2019; 30(6):1745-1753. DOI: 10.1021/acs.bioconjchem.9b00280. View

14.

Jodal A, Pape F, Becker-Pauly C, Maas O, Schibli R, Behe M . Evaluation of ¹¹¹in-labelled exendin-4 derivatives containing different meprin β-specific cleavable linkers. PLoS One. 2015; 10(4):e0123443. PMC: 4391719. DOI: 10.1371/journal.pone.0123443. View

15.

Willard F, Bueno A, Sloop K . Small molecule drug discovery at the glucagon-like peptide-1 receptor. Exp Diabetes Res. 2012; 2012:709893. PMC: 3352573. DOI: 10.1155/2012/709893. View

16.

Salacinski P, Mclean C, Sykes J, Lowry P . Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl glycoluril (Iodogen). Anal Biochem. 1981; 117(1):136-46. DOI: 10.1016/0003-2697(81)90703-x. View

17.

Boerman O, Gotthardt M . 18F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster?. Eur J Nucl Med Mol Imaging. 2011; 39(3):461-2. PMC: 3276772. DOI: 10.1007/s00259-011-2020-9. View

18.

Lexa K, Dolghih E, Jacobson M . A structure-based model for predicting serum albumin binding. PLoS One. 2014; 9(4):e93323. PMC: 3972100. DOI: 10.1371/journal.pone.0093323. View

19.

Dialer L, Jodal A, Schibli R, Ametamey S, Behe M . Radiosynthesis and evaluation of an F-labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma. EJNMMI Radiopharm Chem. 2018; 3(1):1. PMC: 5824708. DOI: 10.1186/s41181-017-0036-6. View

20.

Brom M, Joosten L, Oyen W, Gotthardt M, Boerman O . Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas. Contrast Media Mol Imaging. 2012; 7(2):160-6. PMC: 4246000. DOI: 10.1002/cmmi.475. View